10月2日 - ** Truist Securities将药物开发商Palvella Therapeutics PVLA.O的预测价格从56美元上调至80美元。
** 券商认为Palvella的主要候选药物QTORIN雷帕霉素很有潜力，该药物正在治疗微囊性淋巴畸形的后期试验中。
** 如果试验成功，新适应症取得进展，Truist 将看到该药物的商业机会
** PT的提升也反映了PVLA围绕潜在资本提升的计划。
** 覆盖该股的13位分析师均给予 "买入 "或更高的评级；PT中值为70美元--数据由LSEG编制
** 包括本交易日在内，PVLA股价今年累计上涨约429%。
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.